Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Timing of Tracheotomy in Covid-19 Patients (TTCOV19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04412356
Recruitment Status : Recruiting
First Posted : June 2, 2020
Last Update Posted : June 9, 2020
Sponsor:
Information provided by (Responsible Party):
Henrik Bergquist, Sahlgrenska University Hospital, Sweden

Brief Summary:
Critically ill covid-19 patients may require respiratory support including mechanical ventilation. After an initial period with an endotracheal tube, a tracheotomy is performed in order to reduce potential airway complications, reduce the need of sedation and facilitate the monitoring and recovery. The optimal timing of this surgical procedure is, however, still unknown. The aim of this randomized, controlled trial is to compare the outcome of early (within 7 days) vs late (after at least 10 days) tracheotomy in covid-19 patients. The need for mechanical ventilation, sedation, additional oxygen support, frequency of complications, duration at the ICU and mortality will be evaluated and compared.

Condition or disease Intervention/treatment Phase
Covid-19 ARDS Tracheostomy Complication Respiratory Insufficiency Corona Virus Infection Procedure: Tracheotomy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, single blinded, controlled trial
Masking: Single (Participant)
Masking Description: Patients will be blinded to the randomization outcome.
Primary Purpose: Treatment
Official Title: Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial
Actual Study Start Date : June 4, 2020
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : February 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Early tracheotomy
Tracheotomy within 7 days after intubation.
Procedure: Tracheotomy
Surgical procedure to secure airway

Active Comparator: Late tracheotomy
Tracheotomy after at least 10 days after intubation.
Procedure: Tracheotomy
Surgical procedure to secure airway




Primary Outcome Measures :
  1. Mechanical ventilation [ Time Frame: 28 days ]
    Number of days without mechanical ventilation


Secondary Outcome Measures :
  1. ICU stay [ Time Frame: 28 days ]
    Number of days at ICU

  2. Oxygen support [ Time Frame: 28 days ]
    Number of days with need of additional oxygen support

  3. Sedation [ Time Frame: 28 days ]
    Number of days with the need of sedation

  4. Adverse events [ Time Frame: 28 days ]
    Various adverse events associated with the tracheotomy/tracheostomy

  5. Mortality [ Time Frame: 90 days ]
    Mortality



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Verified Covid-19 infection
  • Intubated due to respiratory insufficiency and need for mechanical ventilation
  • Informed consent from patient or relative

Exclusion Criteria:

  • Age below 18 years
  • Need for mechanical ventilation less than 14 days
  • Tracheotomy not possible within 7 days
  • Tracheotomy not possible due to anatomical or other medical reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04412356


Contacts
Layout table for location contacts
Contact: Henrik Bergquist, Assoc Prof +46 31 3421000 henrik.bergquist@vgregion.se
Contact: Måns Eeg-Olofsson, Assoc Prof +46 31 3421000 mans.eeg-olofsson@vgregion.se

Locations
Layout table for location information
Sweden
Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden
Contact: Henrik Bergquist, Assoc Prof         
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
Investigators
Layout table for investigator information
Principal Investigator: Henrik Bergquist, Assoc Prof Sahlgrenska University Hospital, Sweden
Layout table for additonal information
Responsible Party: Henrik Bergquist, MD, PhD, Associate Professor, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier: NCT04412356    
Other Study ID Numbers: HBergquist
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: June 9, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Henrik Bergquist, Sahlgrenska University Hospital, Sweden:
Covid-19
Tracheotomy
Tracheostomy
RCT
ARDS
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Respiratory Insufficiency
Pulmonary Valve Insufficiency
Virus Diseases
Respiration Disorders
Respiratory Tract Diseases
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections